assessment has been long recognized. Recently, an international effort was initiated to standardize guidance on the kinetic data to be collected in conjunction with toxicity studies. The guidance addresses the kinetic data to be included in studies on carcinogenicity, reproduction toxicity, genotoxicity, and single-and repeatdose toxicity. In various stages of development or implementation, the guidance is intentionally nondetailed regarding the specific kinetic assessments to be performed. This is to allow flexibility in study design and ensures that scientific judgment is used to determine the appropriate kinetic endpoints to achieve study-and drug-specific goals. Some examples of how kinetics have been used at the Food and Drug Administration in review of toxicity studies submitted in drug applications are presented. The examples discussed demonstrate successful and unsuccessful integration of kinetics into study design and interpretation and highlight the impact on the drug development program from a regulatory perspective.
INTRODUCTION
The disposition of a drug in relation to its effects is an important element in interpretation and understanding of a drug's actions. Temporal dispositional information in relation to a drug's desired pharmacodynamic effects at appropriate doses is usually termed pharmacokinetics, while that collected at doses associated with undesired, toxic effects is generally termed toxicokinetics. There are no inherent distinctions in the kinetic parameters that are appropriate for determination of pharmacokinetics versus toxicokinetics. There are differences in the application of the information collected, with pharmacokinetics usually used as an in-depth characterization of the drug's properties, while toxicokinetics is used in assessment of safety. These differences in application often result in differences in the parameters considered most useful and standardly reported as pharmacokinetics versus toxicokinetics. There may also be additional requirements regarding sample collection, analysis, and recordkeeping that are applicable to generation of toxicokinetic data, particularly that conducted as part of or in support of toxicology studies that are subject to Good Laboratory Practices (6) . It is for these reasons and not differences in the underlying scientific principles that a distinction is often made between pharmacokinetics and toxicokinetics. The following discusses some of the guidances that refer to collection and application of toxicokinetic data that have been proposed or are in various stages of implementation under the auspices of the International Conference on Harmonization (ICH) of Technical Requirements for the Registration of Pharmaceuticals for Human Use (2) . Examples of how toxicokinetic information has been used in analysis and interpretation of toxicology studies at the Food and Drug Administration are also discussed.
ICH GUIDANCE ON THE COLLECTION AND USE OF TOXICOKINETIC DATA
The utility of toxicokinetic data for the interpretation of findings and for cross-species toxicity assessment has been long recognized. Recently, an international effort involving the European Community, Japan, and the United States was initiated to harmonize regulatory guidelines for the devel-opment and registration of pharmaceuticals for human use (2) . One aspect of this effort has resulted in the generation of guidelines, which are in various stages of development, concerning preclinical studies for assessing pharmaceutical toxicity. As part of these guidelines, the kinetic data to be collected and analyzed in studies on carcinogenicity, reproduction toxicity, genotoxicity, and single-and repeat-dose toxicity have been delineated. Overall, the approach taken with regard to toxicokinetics has been intentionally nondetailed regarding the specific kinetic assessments to be performed and methodology to be used. This approach has been chosen to allow and encourage flexibility in study design and to ensure that sound scientific judgment is used to determine appropriate kinetic endpoints to achieve study-and drug-specific goals.
Guidances addressing the design and conduct of the individual toxicity studies include discussions of toxicokinetic data that are appropriate to consider in relation to the specific objectives of the particular toxicity study (3, 5, 7) . The guidelines more broadly addressing toxicokinetics summarize this information, suggest some additional considerations important in the design of the toxicokinetic studies to support the toxicity studies, and elaborate on the underlying rationale for the recommendations proposed (4, 6) . The guideline on the Detection of Toxicity to Reproduction for Medicinal Products (3), which is being implemented in the signatory regions, outlines several areas in reproductive toxicity studies in which toxicokinetics may play a valuable role along with standard toxicologic considerations. The areas where kinetics are noted as useful in support of reproductive toxicity studies include considerations of species to be used (relevance to human and availability of kinetic data), the doses selected (high dose as well as dose spread), and route and frequency of administration. It is important to note in referring to the kinetics that the guideline specifically states that &dquo;at the present time the information need not be sophisticated nor derived from pregnant or lactating animals.&dquo; However, &dquo;at the time of study evaluation further information on kinetics in pregnant or lactating animals may be required according to the results obtained.&dquo; Importantly, the document notes that &dquo;to extrapolate the results to humans (assess the relevance), data on likely human exposures, comparative kinetics ... may be helpful.&dquo; From this guidance it is clear that the extent of kinetics collected in conjunction with reproductive toxicity studies should be determined from an examination I of the potential utility of such information to aid in interpreting the findings for each particular therapeutic tested. This philosophy of having the potential utility of the kinetic information drive the tim-ing and extent of the kinetic information that should be collected is a recurrent theme in each of the guidances addressing the collection of kinetics in preclinical studies.
The draft documents on genotoxicity testing and dose selection in carcinogenicity studies provide somewhat more detailed guidance in reference to the specific objectives in using toxicokinetic data than is given in the document on reproduction toxicity testing. The current draft of the consensus document on genotoxicity (7) addresses specific uses of toxicokinetics, including metabolism data. It states that in some cases the appropriateness and validity of negative zn vivo tests may be judged, in part, on pharmacokinetic parameters indicative of &dquo;adequate exposure of the target tissue.&dquo; There is also specific guidance on the biologic compartments to be assessed for exposure. For example, adequacy of exposure may be assessed in an in vivo bone marrow micronucleus test using kinetics by either determining the concentration of drug in the bone marrow or in the plasma compartment. A determination of the methods to be used in making these determinations (e.g., using radiotracer, measurement of parent drug or metabolites, timing of the sampling) are left to the investigator.
A similar approach, where methodology is not specifically defined, is used in the draft Guidance for Dose Selection for Carcinogenicity Studies of Pharmaceuticals (5) . In addition to highlighting the importance of kinetic information for dose-ranging studies to select the doses for carcinogenicity studies, pharmacokinetic-based endpoints for selection of the high dose are defined. These pharmacokinetic endpoints are proposed as equivalent alternatives to the maximum tolerated dose (MTD) for high dose selection. One of the newly proposed endpoints is saturation of &dquo;systemic availability of drug-related substances.&dquo; To use this endpoint in selection of the high dose, it is important to measure parent compound and metabolites. This is to assure that total exposure is maximized and that changes in metabolic disposition of the parent compound are not misinterpreted as saturation of absorption.
A more novel endpoint proposed in the dose selection document is the use of relative area under the concentration-time curve (AUC), rodent to human. &dquo;The selection of a high dose for carcinogenicity studies which represents at a minimum a 25 fold ratio&dquo; is acceptable as an alternative dose to the MTD. Several criteria are listed as being especially applicable for use of this pharmacokinetically defined endpoint (Table I) , emphasizing that this may not be an appropriate endpoint for high dose selection for all therapeutics. For example. this endpoint is not intended for use with therapeutics that are considered genotoxic, nor for drugs where dose-limiting toxicity, which would be considered an MTD, is observed without achieving a 25-fold AUC ratio. The rationale for the ratio proposed is provided in a separate publication (1) . It is derived from analysis of a data base on carcinogenicity studies for drugs tested at the MTD with a comparison of the rodent-to-human AUCs achieved and from an examination of the AUC provided by doses of known human carcinogens necessary to detect tumorigenesis in rodents.
The draft carcinogenicity study dose selection guidance also recommends that kinetics be considered among other factors in selection of the midand low doses for carcinogenicity studies, regardless of the endpoint used to select the high dose. Listed noteworthy kinetic considerations are comparisons of systemic exposure between human and the test species, linearity of a therapeutic's pharmacokinetics over the dose range to be tested in the carcinogenicity study, and saturation of metabolic pathways. While not elaborated on in the document, it is clearly intended that factors be weighted differently in selection of each of the doses over the dose range of the carcinogenicity study. For example, the low dose might be based on achieving an approximately equivalent systemic exposure at the therapeutic dose, the mid-dose on saturation of a metabolic pathway or a specific physiologic effect of the therapeutic in rodents, and the high dose on saturation of absorption or the MTD. Decisions concerning whether or not a particular kinetic endpoint is appropriate for a given therapeutic, and how kinetic and other infarmation is integrated into selection of midand low doses in the carcinogenicity study are left to the judgment of the investigator.
The guidance provided in the 2 draft documents dedicated to toxicokinetics, while providing &dquo;no rigid detailed procedures&dquo; (6) , do give more in-depth guidance on toxicokinetics than is found in any of the documents focusing on toxicity studies. Information is provided on the objectives of the toxicokinetics (including multidose tissue distribution studies), when and how the studies should be conducted, the measurements and parameters that should be considered, how the findings should be analyzed and reported, and applications of the findings in subsequent therapeutic development studies (Table II) (4, 6) . This information is again provided as factors to be considered in the design and conduct of the studies and is guidance on what is generally expected. As in the other documents already discussed, it is clear from these draft documents that for any given therapeutic a greater or lesser extent of toxicokinetic information may be appropriate depending on the toxicology, pharmacology, and intended use of the particular therapeutic. The guidance provided is not intended as check list to be done in all circumstances, regardless of rationale.
It must be emphasized that, with the exception of the document addressing reproduction toxicity testing, these are at present all in draft form and subject to revision. Even the general guidance provided is subject to change as the documents undergo revision as part of the ICH process. When finalized, these documents will ensure uniform regulatory requirements for toxicokinetics across the signatory regions and highlight the importance of information on a therapeutic's disposition for use in support of toxicology studies. Clearly, in all the documents it is emphasized that developing a toxicokinetics program for a given drug is to be an iterative process in conjunction with developments in the toxicology program and should be integrated into the overall development plan. The extent of the information appropriate for any given therapeutic should be assessed by both the sponsor and the regulatory agencies in consideration of the need for and value added by the collection of the additional information. Factored into this assessment should be the possible use of additional animals and the impact of sample collection on toxicity study endpoints as well as any potential contribution to better understanding the therapeutic or enhancement of the clinical program that may ensue.
CASE STUDIES OF FOOD AND DRUG ADMINISTRATION EXPERIENCE IN

APPLICATION OF KINETIC DATA IN
REVIEW OF INVESTIGATIONAL NEW DRUG SUBMISSIONS
Extensive kinetic data from preclinical studies is not a current or past requirement under Food and Drug Administration (FDA) regulations addressing Investigational New Drug (IND) applications or New Drug Applications (NDAs). However, in recent years kinetic data from preclinical species have usually been included in both types of submissions to varying extents. When it has not been included or has been determined to be inadequate, kinetic data have often been requested to support toxicology studies and to aid in interpretation of toxicity findings. The kinetic parameters, determined at both pharmacologic and toxicologic doses, provide the most utility when available for examination contemporaneously with the review of the pharmacology and toxicology study results. When the analytic methods make it possible, efforts should be made to collect and submit this information concomitantly with the preclinical pharmacodynamic study submissions. The interpretation and evaluation of toxicity study findings, both within a given study and across studies and species, are often significantly influenced by the availability of kinetic data. Four case studies of how such kinetic information has been used in assessing toxicity findings submitted in drug applications, and the influence this information has had on regulatory decisions is presented below. The examples discussed demonstrate the need to integrate kinetics into study design and interpretation and highlight the impact on the drug development program. The examples given are not identified by drug or drug class, as the data are derived from IND submissions. It should be noted that in the examples provided, where the kinetic data were not adequate to address a particular problem, in all likelihood the kinetic studies were not designed to address the questions asked based on regulatory concerns. As such, they should not be perceived as failures in the drug development process but, rather, as illustrations of the importance of an integrated assessment of kinetic information to support toxicity studies and drug development overall.
Case Study 7
The first example is from a drug combination. A sponsor wanted to test a new investigational agent as an add-on therapy with a marketed drug. The investigational agent and the marketed drug had been extensively tested as single agents in preclinical and clinical studies. When the sponsor presented their IND development plan, it was recommended that they conduct a 1-mo combination toxicity study in rats and determine whether or not kinetic or toxic interactions occurred as a result of the combination treatment. The marketed drug alone at high doses (50 mg/kg/day) caused mortality in 20% of the animals when administered for I mo. Previous data indicated that high doses (>25 mg/kg/day) of the investigational agent could also cause mortality in rodents with I mo of administration. When administered for 1 mo alone at low doses, the marketed drug (10 mg/kg/day) and the investigational agent (5 mg/kg/day) produced no mortality. However, when these low doses of the 2 drugs were admin- istered in combination, mortality was observed in > 90% of the animals in less than 2 wk. Although only single-dose kinetics were assessed, a > 2-fold increase in the AUC of the investigational agent in the presence of the marketed drug was observed. This increase was not accompanied by an increase in the single dose Cmax but was associated with an increase in the t,h such that repeated dosing would lead to higher Css. Pharmacokinetic parameters for the marketed drug were unaltered in the combination. The identification in preclinical studies of altered kinetics for the investigational agent in the combination treatment in association with increased toxicity was vital in designing appropriate clinical monitoring procedures and starting doses of both drugs to allow clinical development of the combination.
Case Study 2
The second example illustrates how kinetic data can be used in interpretation of toxicity studies and in assessing their adequacy. A sponsor requested a TABLE IIL-Segment II reproductive studies conducted in the rat and rabbit.
Abbreviation: ns = not statistically significant.
-Absorption at this dose is saturated. change in labeling regarding reproductive toxicity for a marketed drug that had previously not been tested. Teratology studies were conducted in rats and rabbits with the drug administered by gavage at 90-100-fold the clinical oral dose (Table III) . Clinically, the drug is administered by both the oral and intravenous routes, with the intravenous dose > 15-fold that of the oral dose. In both species tested, the studies indicated that there was no toxicity observed in the Fo generation and minimal evidence of a reproductive hazard. However, data available for rats indicate that oral bioavailability is low at the doses tested (similar information is unavailable for the rabbit). At clinical doses in humans, oral bioavailability is high, although saturation of absorption occurs. Comparison of human systemic exposure following oral administration with that achieved in rat at the highest dose tested in the teratology studies indicates that the systemic exposure is approximately equivalent, even though the doses in rodent are many-fold greater. Human systemic exposure by the intravenous route is approximately 50-fold greater than that achieved at the highest dose tested in the teratology studies. As a result of the low systemic exposure in the rat, and the similar (or greater) systemic exposure achieved in humans, it was concluded that the reproductive toxicity information available was inadequate to warrant a change in labeling. Based on the kinetic data available, it could not be concluded that this drug did not offer a potential reproductive hazard for humans. It must be reiterated that in neither test species were the doses selected based on observed toxicity in the Fo generation. Thus. toxicity did not limit the high dose or indicate that an adequate test of reproductive toxicity had been performed. It was recommended that the sponsor repeat the studies by a route that resulted in greater exposure or select doses based on toxicity endpoints for the reproductive studies.
Case Study 3
The third example reflects how preclinical kinetic data can be used to facilitate a rational clinical drug development program. A therapeutic was being developed primarily for an indication for use in women. Preclinical studies conducted in both male and female animals demonstrated few gender-based differences in toxicity. Analysis of preclinical kinetics also showed no gender-based difference in total systemic exposure (drug plus related compounds) as assessed by oral administration of radiolabeled drug to rats. However, there was significant metabolism of parent compound in both sexes; in males, parent compound represented < 10% of the total exposure, compared to > 50% of the total exposure in females. Nearly identical results were obtained with iv administration. Male dogs also showed extensive and rapid conversion of parent compound to metabolites. Female dogs were not examined. Pharmacokinetic studies in humans showed a 6-fold genderbased difference in systemic exposure to parent compound, similar to that observed in rats. The clinical development proceeded from Phase I studies in male volunteers, followed by extensive pharmacokinetic studies in males. Only during Phase 2 were kinetics examined in females, even though the drug was targeted for an indication primarily for use in females. Had the gender-based differences in kinetics observed in the rodent study been appreciated and further examined in the dog, it is possible that a different clinical development plan would have emerged. Possibly, examination of potential genderbased differences in human pharmacokinetics would have preceded initiation of clinical Phase 2 studies, with a less extensive examination of the pharmacokinetics in male subjects. An approach so modified may have used drug development resources more efficiently. Case Study 4
The final example illustrates how the application of kinetic data can be used to assist in rational toxicology study design. A 13-wk dietary administration dose-ranging study in male and female rats was submitted to the FDA with a request for concurrence with a proposal for doses to be used in a carcinogenicity study. The high dose was selected based on observation of significant toxicity, a MTD. Severe reduction in body weight gain, organ weight changes, alterations in clinical chemistries, and histopathology was observed. In general, these changes were seen only at doses above which large reductions in food consumption were also noted. There was a concern that these findings may have been associated with reduced food consumption as a result of lack of palatability of the drug and food admixture. This was supported by a previously submitted 3-mo oral gavage study conducted in the same strain of rat that had used doses 3-fold greater before encountering significant toxicity. The ability to use substantially higher doses by gavage administration initially suggested to FDA reviewers that gavage administration might be more appropriate for conduct of the carcinogenicity study for this drug. However, the sponsor had also collected toxicokinetic data from the dietary study and had previously submitted kinetic data from the gavage study. Analysis of this data by FDA reviewers revealed that different doses by gavage and dietary administration yielded equivalent toxicity at approximately equivalent systemic exposures. Differences in systemic exposure at equivalent doses in males and females also largely accounted for gender-based differences in sensitivity to the drug. Given this information, it was clear that use of higher gavage doses in a carcinogenicity study would not result in a more rigorous test of the carcinogenic potential of this drug, as the systemic exposure would not have been increased over that achieved by dietary administration. Furthermore, these findings suggested that the toxicity observed was not associated with decreased food consumption as a result of decreased food palatability in the dietary study. Thus, based on the kinetic information, FDA reviewers were able to concur with the sponsor's proposed doses using dietary administration. Given the toxicity information available for gavage and dietary administration in the absence of the kinetic data, it is likely that a carcinogenicity study using gavage administration at the higher doses would have been recommended.
CONCLUSIONS
The preceding discussion and examples illustrate how assessment of kinetics have become an important, integral component of preclinical toxicity testing and drug review. As apparent by reference in the ICH documents on toxicity testing and from the case studies described, kinetics assessments should be undertaken using scientific judgment. The resulting data should be viewed as an additional tool to aid in designing studies, interpreting findings, and evaluating the relevancy of preclinical findings to humans. To facilitate achieving these objectives, consideration should be given to evaluating and presenting comparative kinetics, including human data, as soon as the relevant information becomes available. This is especially appropriate in the initial phases of drug development, where choices in preclinical study design and species/strains may be more readily influenced by assessment of this information. In some instances using preclinical kinetic data can alter and expedite clinical development. Most importantly, the preceding illustrates how kinetic information should be integrated into the overall drug development program.
